Allergan: CRT Capital believes that VRX could up their bid for AGN by $5bn on the cash side (161.28)
CRT Capital believes that VRX could up their bid for AGN by $5bn on the cash side to make it a $52bn offer -- they say this would still give them 18-20% eps accretion in year 1, as well as $2.7bn in cost synergies equaling $9-10 in upside to AGN.